Rua Bioscience

Rua Bioscience FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Rua Bioscience (RUA.NZ) as of Oct 18, 2026 is 80.76 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 27.25 % — a change of 196.42% (higher).

FCF Conversion

80.76 %

YoY

196.42%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Rua Bioscience is 2025 80.76 % . FCF Conversion Rate (FCF/EBITDA) of Rua Bioscience was 2024 27.25 % . It decreases by 196.42% higher compared to the previous year.

The Rua Bioscience FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
122.31 NZD
Jan 1, 2020
307.44 NZD
Jan 1, 2021
132.40 NZD
Jan 1, 2022
83.89 NZD
Jan 1, 2023
100.58 NZD
Jan 1, 2024
27.25 NZD
Jan 1, 2025
80.76 NZD
The Rua Bioscience FCF Conversion history
YEARFCF ConversionYoY
80.76 %+196.42%
27.25 %-72.91%
100.58 %+19.89%
83.89 %-36.64%
132.40 %-56.93%
307.44 %+151.36%
122.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Rua Bioscience Stock analysis

What does Rua Bioscience do? Rua Bioscience Ltd, trading as RUA.NZ, is a pharmaceutical company headquartered in Gisborne, New Zealand. The company operates in the Health Care sector, specifically within Pharmaceuticals. It conducts research and development, and engages in pharmaceutical distribution and marketing. Rua Bioscience focuses on breeding, cultivating, manufacturing, and supplying medicinal cannabis products. The firm operates through one segment, offering research and development services and pharmaceutical products in Germany and New Zealand. It maintains a full research laboratory in Gisborne for cannabinoid testing, microscopic analysis, moisture analysis, sample preparation, extraction, solvent removal, viscosity measurements, and impurity testing. The company completed its IPO on October 22, 2020. Rua Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rua Bioscience stock

FCF Conversion Rate (FCF/EBITDA) of Rua Bioscience is 80.76 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Rua Bioscience changed from 27.25 % to 80.76 %, representing a 196.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Rua Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Rua Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Rua Bioscience

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Rua Bioscience